References
- Redman J R, Cabanillas F, Velasquez W S, McLaughlin P, Hagemeister F B, Swan F, et al. Phase II trial of fludarabine phosphate in lymphomas: an effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790–794
- Hochster H S, Kim K, Green M D, Mann R B, Neiman R S, Oken M M, et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992; 10: 28–32
- McLaughlin P, Hagemeister F B, Romaguera J E, Sarris A H, Pate O, Younes A, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262–1268
- Zinzani P L, Bendandi M, Magagnoli M, Gherlinzoni F, Merla E, Tura S. Fludarabine – mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol 1997; 8: 379–383
- Younes A, Ayoub J P, Sarris A, Hagemeister F, North L, Pate O, et al. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol 1997; 96: 328–332
- Wilson H W, Chabner B A, Bryant G, Bates S, Fojo A, Regis J, et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 1995; 13: 381–386
- Younes A, Rodriguez M A, McLaughlin P, North L, Sarris A H, Pate O, et al. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1997; 26: 77–82
- Seymour J F, Grigg A P, Szer J, Fox R M. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Ann Oncol 2001; 12: 1455–1460
- Jazirehi A R, Gan X H, De Vos S. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003; 2: 1183–1193